The incretin hormones glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐
like peptide‐1 (GLP‐1) have their main physiological role in augmenting insulin secretion …

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its “incretin effect”
in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a …

Background In 1982, Braunwald and Kloner 1 described stunning as “prolonged, post‐
ischemic ventricular dysfunction that occurs after brief periods of nonlethal ischemia.” They …

The impressive results of recent clinical trials with glucagon-like peptide-1 receptor agonists
(GLP-1Ra) and sodium glucose transporter 2 inhibitors (SGLT-2i) in terms of cardiovascular …

Unlike acute myocardial infarction with reperfusion, in which infarct size is the end point
reflecting irreversible injury, myocardial stunning and hibernation result from reversible …

Cardiovascular outcome trials revealed cardiovascular benefits for type 2 diabetes mellitus
patients when treated with long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonists …

Acute myocardial infarction (AMI) is one of the leading causes of mortality and morbidity
worldwide. There has been an extensive search for cardioprotective therapies to reduce …

Mitochondrial dysfunction and associated oxidative stress are strongly linked to
cardiovascular, neurodegenerative, and age associated disorders. More specifically …